| Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting (NCT07542314) | Sarepta Therapeutics, Inc. | 2026-07-31 |
| A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease (NCT07536061) | Sarepta Therapeutics, Inc. | 2026-05-12 |
| A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants (NCT06952686) | Sarepta Therapeutics, Inc. | 2025-06-30 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States (NCT06747273) | Sarepta Therapeutics, Inc. | 2025-01-09 |
| Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 (NCT06131983) | Sarepta Therapeutics, Inc. | 2024-06-19 |
| Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy (NCT06138743) | Sarepta Therapeutics, Inc. | 2024-03-04 |
| An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy (NCT06270719) | Sarepta Therapeutics, Inc. | 2024-02-07 |
| A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) (NCT06241950) | Sarepta Therapeutics, Inc. | 2024-01-29 |
| A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (NCT06246513) | Sarepta Therapeutics, Inc. | 2024-01-15 |
| A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (NCT05967351) | Sarepta Therapeutics, Inc. | 2023-09-27 |
| A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (NCT05881408) | Sarepta Therapeutics, Inc. | 2023-05-31 |
| A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) (NCT05906251) | Sarepta Therapeutics, Inc. | 2023-05-22 |
| A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) (NCT05876780) | Sarepta Therapeutics, Inc. | 2022-12-19 |
| A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (NCT05096221) | Sarepta Therapeutics, Inc. | 2021-10-27 |
| A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice (NCT04475926) | Sarepta Therapeutics, Inc. | 2021-04-22 |
| A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort (NCT04626674) | Sarepta Therapeutics, Inc. | 2020-11-23 |
| A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) (NCT03992430) | Sarepta Therapeutics, Inc. | 2020-07-13 |
| Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (NCT04004065) | Sarepta Therapeutics, Inc. | 2019-06-26 |
| A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995) (NCT03985878) | Sarepta Therapeutics, Inc. | 2019-06-26 |
| A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice (NCT06606340) | Sarepta Therapeutics, Inc. | 2019-01-07 |
| An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen) (NCT03675126) | Sarepta Therapeutics, Inc. | 2018-12-19 |
| A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) (NCT03769116) | Sarepta Therapeutics, Inc. | 2018-12-05 |
| Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) (NCT03652259) | Sarepta Therapeutics, Inc. | 2018-10-27 |
| An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy (NCT03532542) | Sarepta Therapeutics, Inc. | 2018-08-02 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD) (NCT03375255) | Sarepta Therapeutics, Inc. | 2018-02-05 |
| A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (NCT03375164) | Sarepta Therapeutics, Inc. | 2018-01-04 |